51. The method according to claim 49 wherein said anti-fibrotic agent is said protein and said protein is an antibody or a soluble form of said receptor.

52. The method according to claim 51 wherein said antibody is an anti-TGF-β_1, anti-TGF-β_2 or anti-PDGF antibody.

53. The method according to claim 47 wherein said TGF-β_3 is provided at said site in an inactive form that is converted to an active form at said site.

54. The method according to claim 47 wherein said TGF-β_3 is provided at said site in a pharmaceutical composition comprising a pharmaceutically acceptable carrier.

55. The method according to claim 54 wherein said carrier comprises a biopolymer.--

REMARKS

Entry of the foregoing amendments is respectfully requested.

New claims 38 to 55 have been added. The newly presented claims find support throughout the disclosure, including in the claims as originally filed. Further, the new claims are submitted to be both novel and unobvious over the art of record.

FERGUSON et al -- Serial No. 08/307,640

This application is submitted to be in condition for allowance and a Notice to that effect is requested.

Respectfully submitted,

NIXON & VANDERHYE, P.C.

By Mary J. Wilson
Mary J. Wilson
Reg. No. 32,955

MJW:tat

1100 North Glebe Road
8th Floor
Arlington, Virginia 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100